1.81 USD
-0.1 (-5.24%)
1.82 USD
+0.01 (+0.55%)
Taking everything into account, AUTL scores 3 out of 10 in our fundamental rating. AUTL was compared to 530 industry peers in the Biotechnology industry. AUTL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AUTL is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year AUTL has reported negative net income.
AUTL had a negative operating cash flow in the past year.
AUTL had negative earnings in each of the past 5 years.
AUTL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of AUTL (-33.96%) is better than 63.77% of its industry peers.
AUTL has a Return On Equity of -84.69%. This is comparable to the rest of the industry: AUTL outperforms 50.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.96% | ||
| ROE | -84.69% | ||
| ROIC | N/A |
ROA(3y)-38.02%
ROA(5y)-39.48%
ROE(3y)-96.13%
ROE(5y)-80.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for AUTL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AUTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AUTL has an improved debt to assets ratio.
2.2 Solvency
AUTL has an Altman-Z score of -2.48. This is a bad value and indicates that AUTL is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.48, AUTL perfoms like the industry average, outperforming 47.55% of the companies in the same industry.
A Debt/Equity ratio of 0.95 indicates that AUTL is somewhat dependend on debt financing.
The Debt to Equity ratio of AUTL (0.95) is worse than 74.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.48 |
ROIC/WACCN/A
WACC7.71%
2.3 Liquidity
A Current Ratio of 6.19 indicates that AUTL has no problem at all paying its short term obligations.
AUTL has a better Current ratio (6.19) than 63.40% of its industry peers.
AUTL has a Quick Ratio of 5.86. This indicates that AUTL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.86, AUTL is in the better half of the industry, outperforming 62.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.19 | ||
| Quick Ratio | 5.86 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 31.15% over the past year.
The Revenue has grown by 496.00% in the past year. This is a very strong growth!
AUTL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.31% yearly.
EPS 1Y (TTM)31.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.23%
Revenue 1Y (TTM)496%
Revenue growth 3Y63.16%
Revenue growth 5Y28.31%
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, AUTL will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.62% on average per year.
The Revenue is expected to grow by 117.77% on average over the next years. This is a very strong growth
EPS Next Y-13.2%
EPS Next 2Y5.08%
EPS Next 3Y11.48%
EPS Next 5Y18.62%
Revenue Next Year503.05%
Revenue Next 2Y239.86%
Revenue Next 3Y180.48%
Revenue Next 5Y117.77%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AUTL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AUTL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.08%
EPS Next 3Y11.48%
5. Dividend
5.1 Amount
AUTL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.81
-0.1 (-5.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.79%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap481.72M
Revenue(TTM)51.13M
Net Income(TTM)-224.80M
Analysts85.88
Price Target9.35 (416.57%)
Short Float %4.92%
Short Ratio4.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.59%
Min EPS beat(2)-30.31%
Max EPS beat(2)25.13%
EPS beat(4)2
Avg EPS beat(4)11.3%
Min EPS beat(4)-30.31%
Max EPS beat(4)52.34%
EPS beat(8)2
Avg EPS beat(8)-51.27%
EPS beat(12)4
Avg EPS beat(12)-32.86%
EPS beat(16)6
Avg EPS beat(16)-24.54%
Revenue beat(2)1
Avg Revenue beat(2)28.11%
Min Revenue beat(2)-2.73%
Max Revenue beat(2)58.95%
Revenue beat(4)2
Avg Revenue beat(4)70.92%
Min Revenue beat(4)-99.05%
Max Revenue beat(4)326.5%
Revenue beat(8)2
Avg Revenue beat(8)-9.59%
Revenue beat(12)4
Avg Revenue beat(12)7.38%
Revenue beat(16)5
Avg Revenue beat(16)97.39%
PT rev (1m)-2.56%
PT rev (3m)-3.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.28%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.62%
Revenue NY rev (1m)1.5%
Revenue NY rev (3m)3.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 9.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.81 | ||
| P/tB | 1.96 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0.19
BVpS1
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.96% | ||
| ROE | -84.69% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-38.02%
ROA(5y)-39.48%
ROE(3y)-96.13%
ROE(5y)-80.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 560.18% | ||
| Cap/Sales | 101.46% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.19 | ||
| Quick Ratio | 5.86 | ||
| Altman-Z | -2.48 |
F-Score2
WACC7.71%
ROIC/WACCN/A
Cap/Depr(3y)254.9%
Cap/Depr(5y)225.76%
Cap/Sales(3y)387.17%
Cap/Sales(5y)479.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.23%
EPS Next Y-13.2%
EPS Next 2Y5.08%
EPS Next 3Y11.48%
EPS Next 5Y18.62%
Revenue 1Y (TTM)496%
Revenue growth 3Y63.16%
Revenue growth 5Y28.31%
Sales Q2Q%N/A
Revenue Next Year503.05%
Revenue Next 2Y239.86%
Revenue Next 3Y180.48%
Revenue Next 5Y117.77%
EBIT growth 1Y-37.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.78%
EBIT Next 3Y9.29%
EBIT Next 5Y23.74%
FCF growth 1Y-110.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.84%
OCF growth 3YN/A
OCF growth 5YN/A
AUTOLUS THERAPEUTICS PLC / AUTL FAQ
What is the fundamental rating for AUTL stock?
ChartMill assigns a fundamental rating of 3 / 10 to AUTL.
What is the valuation status of AUTOLUS THERAPEUTICS PLC (AUTL) stock?
ChartMill assigns a valuation rating of 0 / 10 to AUTOLUS THERAPEUTICS PLC (AUTL). This can be considered as Overvalued.
How profitable is AUTOLUS THERAPEUTICS PLC (AUTL) stock?
AUTOLUS THERAPEUTICS PLC (AUTL) has a profitability rating of 1 / 10.
Can you provide the financial health for AUTL stock?
The financial health rating of AUTOLUS THERAPEUTICS PLC (AUTL) is 4 / 10.
What is the earnings growth outlook for AUTOLUS THERAPEUTICS PLC?
The Earnings per Share (EPS) of AUTOLUS THERAPEUTICS PLC (AUTL) is expected to decline by -13.2% in the next year.